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Summary.-A proven biochemical method for assessing chemically induced neuro-
toxicity has been applied to the study of the toxic effects of misonidazole (MISO) in
the rat. This involves the fluorimetric measurement of f-glucuronidase and /B-
galactosidase activities in homogenates of rat nervous tissue. The tissues analysed
were sciatic/posterior tibial nerve (SPTN) cut into 4 sections, trigeminal ganglia and
cerebellum. MISO administered i.p. to Wistar rats in doses >300 mg/kg/day for 7
consecutive days produced maximal increases in both /3-glucuronidase and/3-galacto-
sidase activities in the SPTN at 4 weeks (140-180% of control values). The highest
increases were associated with the mostdistalsectionofthenerve. Significantenzyme-
activity changes were also found in the trigeminal ganglia and cerebellum of MISO-
dosed rats. The greatest activity occurred 4-5 weeks after dosing, and was dose-
related.
It is concluded that, in the rat, MISO can produce biochemical changes consistent
with a dying-back peripheral neuropathy, and biochemical changes suggestive of
cerebellar damage. This biochemical approach would appear to offer a convenient
quantitative method for the detection of neurotoxic effects of other potential radio-
sensitizing drugs.
THE 2-NITROIMIDAZOLE, mnisonidazole
(Ro-07-0582, MISO) is at present under-
going clinical trials in many radiotherapy
centres as a potential sensitizer of radio-
resistant hypoxic cells (Dische et al., 1977;
Urtasun et al., 1977). However, the clinical
effectiveness of MISO and other com-
pounds which might be useful radiosensi-
tizers is limited by neurotoxicity (Dische
et al., 1977; Coxon & Pallis, 1976; Le
Quesne, 1975). When MISO is given in a
fractionated course during radiotherapy,
the toxicity first manifests itself as a mild
peripheral sensory neuropathy (Dische et
al., 1977; Urtasun et al., 1977) and when
administration of the drug is continued,
some severe convulsions have been ob-
served (Saunders et al., 1978). These
contraindications have led to a maximum
total drug-dose of 12 g/m2 being adopted
(Dische, 1977) the consequence ofwhich is
that MISO cannot be used at its optimum
radiosensitizing dose. This has led to
the search for second-generation hypoxic
cell radiosensitizers, based on the nitro-
imidazole structure, that might be clinic-
ally more effective than MISO.
A central requirement for future drug
development is an estimation of the prob-
able neurotoxic effect of any promising
radiosensitizer. As a first step, the effect
of single and multiple doses of MISO on
various functional, behavioural and patho-
logical end-points in rodents have been
examined. These systems, which include
measurement ofnerve conduction velocity
(Conroy et al., 1979; Hirst et al., 1978,
1 979) electron and light microscopy of
peripheral nerves and CNS (Adams et al.,
1980; Conroy et al., 1979) and behavioural
tests such as rota-rod and foot-splay drop-
test (Conroy et al., 1979) have shown thatBIOCHEMICAL ASSESSMENT OF MISONIDAZOLE NEUROTOXICITY
in vivo changes can occur after treatment
with MISO. However, it is apparent that
quantifying such changes in order to
identify a superior drug would not be
easy.
We report here one way in which a
reliable quantitative comparison of the
neurotoxicities of different radiosensitizers
can be made. In our laboratory we have
developed a biochemicalmethodfordetect-
ing chemically induced peripheral neuro-
pathies. This method involves measuring
the enzymes 3-glucuronidase and f-
galactosidase in homogenates of rat ner-
votls tissue (Dewar & Moffett, 1979). The
justification for measuring the activities
of these two enzymes is that they have
been shown to increase dramatically
during the second phase of Wallerian
degeneration (Hollinger & Rossiter, 1952;
McCaman & Robins, 1959), i.e. during the
period of proliferation of Schwann cells
and macrophages. The majority of chemi-
cally induced peripheral neuropathies
(with certain exceptions such as lead) are
of the primary axonal type and resemble
WI'allerian degeneration in many respects
(Cavanagh, 1973). Therefore, we con-
sidered it justifiable to take an increase
in the activity of these two enzymes as
evidence ofdegeneration. We have success-
fully applied this approach to the study of
the neurotoxicity of several pesticides and
industrial chemicals (Dewar & Moffett,
1979; Dewar et al., 1979).
AWe report here the results of applying
this approach to the stu(ly ofMISO neuro-
toxicity. We have examined the effect of
subacute administration of MISO on the
3-glucuronidase and f-galactosidase acti-
vities of the sciatic/posterior tibial nerve
of the Wistar rat. In view of the evidence
that MISO produces a sensory neuropathy
in man (Dische et al., 1-977; Urtasun et al.,
1977) and that nitroimidazole derivatives
can produce cerebellar damage in the dog
(Scharer, 1972) the trigeminal ganglia and
cerebellum were also analysed. Part of
this work has been presented as a pre-
liminary communication (Rose et al.,
1979).
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METHODS
Anirnals
Wistar rats bred under specified pathogen-
free conditions in the Shell Toxicology
Laboratory (Tunstall) Breeding Unit were
used throughout. At the start of each of the
two experiments the rats were 10-12 weeks
old. Beforeand afterdosing theywere supplied
Aith food and water ad libitum.
Dosing
Misonidazole (Ro-07-0582) (1-(2-nitro-1 -
imidazolyl)-3-methoxy-2-propanol) was ad-
ministered as a 5, 10 or 20%0 w/v solution in
propylene glycol (Sigma Chemical Co. Ltd).
In Experiment 1, 40 male and 40 female
Wistar rats received 7 coinsecutive daily
doses of MISO 400 mg/kg/day. A control
group of 25 male and 25 female AWistar rats
received 7 consecutive daily doses of propy-
lene glycol 2 ml/kg/day. Toxicological signs
and body weights were documented through-
out the experiment. A high dose ofMISO was
chosen to ensure that any biochemical corre-
lates of the drug-induced neuropathy would
be detectable.
In Experiment 11, 5 groups of male WATistar
rats (10 per group) received 50, 100, 200, 300
and 500 mg/kg/day MISO for 7 consecutive
days. A 6th (control) group received propy-
leneglycol 2 ml/kg/day for 7 consecutive days.
Preparation of tissue
The rats were killed by cervical dislocation.
In Expt I, the right and left sciatic nerves
were dissected from the spinal cord to the
most distal phalangeal branches of the pos-
terior tibial nerve. The length of nerve was
then cut into 4 sections ranging from the
most distal (Section A) to the most proximal
(Section D) as illustrated in Fig. 1. In Expt IT,
only the two most distal sections ofthe nerve
(A and B) were analysed. In both experi-
ments, the trigeminal ganglia and cerebellum
were removed from the skull and cleared of
any extraneous tissue. Each tissue sample
(with the exception of the cerebellum) was
wAeighed and homogenized in a volume of ice-
cold (0-40C) 0 1M sodium acetate buffer
(pH 4 5) containing 0-1% v/v Triton X-100,
calculated to yield a 1% w/v homogenate. In
the case of the cerebellum a 0-500 w/v homo-
genate was prepared using the same solutions.
These homogenates were used for all subse-
quent enzyme assays. In Expt I, the enzymes
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FIG. 1. A diagrammatic representation ofthe
sciatic/posterior tibial nerve in a Wistar
rat, showing the 4 sections taken for lyso-
somal enzyme measurements.
3-glucuronidase and /-galactosidase were
assayed at 1, 2, 3, 4, 5, 6, 8 and 12 weeks after
the start of dosing. In Expt II, the enzymes
were assayed after 4 weeks.
Enzyme assays
The /3-glucuronidase and /-galactosidase
activities were measured by methods adapted
from those described by Fishman et at. (1948),
Robins et at (1961) and Dewar et al. (1975).
(a) /3-Galactosidase.-A 0-2ml aliquot of
each tissue homogenate was diluted with
0-2 ml of 01M glycine-HCl buffer (pH 3.0)
and added to 1 ml of 1mM methylumbelliferyl
galactoside dissolved in 01M glycine-HCl
buffer (pH 3.0). The buffered substrate had
been pre-incubated for 10 min at 37°C in
1-5ml Eppendorf polypropylene tubes. After
the contents had been thoroughly mixed,
each tube was incubated for 1 h at 37°C in a
Techne Dri-Bloc heating unit. The tubes were
then centrifuged for 2 min at 10,000 g in an
Eppendorf microcentrifuge, and the super-
natant was decanted into 2 ml of 0-1M
Na2CO3. The fluorescence was measured on a
MSE Vitatron (excitation wavelength 365
nm, emission wavelength 450 nm). Standards
were prepared by taking 0-01-0 20ml aliquots
of a 150uM solution ofmethylumbelliferone in
distilled water and diluting to a final volume
of 0 4 ml. This corresponded to a range of
0-26-5-28 jug methylumbelliferone. To each
diluted standard was added 1 ml 01M
glycine-HCl buffer and 2 ml of0dIM Na2CO3.
The fluorescence was measured as described
above. 3-Galactosidase activity was expressed
as ,ug methylumbelliferone liberated/h/mg
(wet weight).
(b) f3-Glucuronidase.-A 0-5ml aliquot of
each tissue homogenate was placed in a 1 5ml
polypropylene tube and diluted with 0 5 ml
of 01M sodium acetate buffer (pH 4.5). A
0Iml aliquot of 1mM methylumbelliferyl
glucuronide was added, and the contents of
each tube were thoroughly mixed, incubated
for 2 h at 37°C and then centrifuged for 2 min
at 10,000 g. The supernatant was then
decanted into 2-3 ml 01M Na2CO3 and the
fluorescence was measured as for /-galactos-
idase. The methylumbelliferone liberated was
calculated by reference to the methyl-
umbelliferone standard curve, the prepara-
tion of which is described under (a). The
3-glucuronidase activity was expressed as ,ug
methylumbelliferone liberated/h/mg (wet
weight). The liberation ofthe fluorescent pro-
duct methylumbelliferone has been shown in
our laboratory (Rose & Dewar, unpublished)
and by McCaman & Robins (1959) to be linear
for at least 10 h. The substrates used also gave
negligible fluorescence under the above con-
ditions, and non-enzymatic hydrolysis was
not detected by the above method.
RESULTS
Rats dosed with 400 mg/kg/day MISO
became progressively more lethargic. This
was accompanied by a reduction in the
rate of respiration, hypothermia and
cyanosis of the limb extremities, tail and
scrotum. After 5 doses (a cumulative dose
of 2 g/kg) the rats showed reduced muscle
tone, hunched hindquarters and an abnor-
mal (tip-toe) hindlimb gait. These signs
were seen in most of the animals, and
lasted for up to 3 weeks from the start
of dosing. Twelve of the animals died,
mostly in the first week after dosing.
,3-Glucuronidase and ,3-galactosidase ac-
tivities in the sciatic/posterior tibial nerves
(SPTN) are shown in Figs 2 and 3. The
MISO-dosed animals showed greater nerve
3-glucuronidase and /3-galactosidase acti-
vities than the propylene glycol-dosed
controls. These increases were maximal
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TABLE I.-Effect ofincreasing doses ofmisonidazole on the /3-glucuronidase and /3-galacto-
sidase activities in distal sections ofthe sciatic/posterior tibial nerve ofmale Wistar rats
Enzyme activity expressed as ug of methylumbelliferone liberated/h/mg
(wet weight) (means +s.e.) __l~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Section A
mg/kg) ,B-Glucuronidase
0 0 34+0-01
(20)
350 0*33 + 0-01
[96.2%]
(20)
700 0 34+ 0-01
[100.0%]
(22)
1400 0 37+ 0-01
[107.9%]
(14)
2100 0.40+ 0-01
[118-1%]
(14)
3500 0.53 + 0-04***
[156-3%]
(6)
fl-Galactosidase
1-39+ 0*05
(20)
1.40+ 0 04
[100I6%]
(20)
1-51 + 0.04
[108-4%]
(22]
1*49 + 0-06
[107.0%]
(14)
1-68+ 0.05**
[120.6%]
(14)
1*87 +011***
[134-5%]
(6)
Section B
,-Glucuronidase ,-Galactosidase
0-25 + 0-01 1*08 + 0*03
(20) (20)
0*26+ 0*01 1-12+0*03
[102X0%] [103.9%]
(20) (20)
0-25+0-01 1-17+0*04
[100.0%] [107.8%]
(22) (22)
0-27 + 0*01 1*17+ 0-05
[106-3%] [108-2%]
(14) (14)
0-28 + 0-01** 1-22 + 0.04*
[111.5%] [113-0%]
(14) (14)
0*32 + 0-01*** 1*31 + 0.04***
[124.5%] [121.3%]
(6) (6)
Significant difference from control: *P < 0 05, **P < 0.01, ***P < 0.001.
Enzyme activity measured 4 weeks after the start of dosing.
TABLE II.-Effect of the subacute administration of MIISO on the fi-glucuronidase and
/3-galactosidase activities in the trigeminal ganglia of male andfemale Wistar rats
Enzyme activity expressed as ,ug of methylumbelliferone liberated/h/mg
(wet weight)
M
Time of ,B-Glucuronidase
analysis Propylene glycol MISO
(weeks) 2 ml/kg/day 400 mg/kg/day
1 0-31+0.01 0.35 + 0-01***
(12) [113-3%]
(18)
2 0*24+ 0-02 0-21 + 0-01**
(10) [86.4%]
(18
3 0-19+0.01 0-21+0-01
(14) [106-8%]
(18)
4 0K19+0-01 0-28 + 0-02**
(10) [145-9%]
(10)
5 0*21+0-01 0-31 + 0-01***
(12) [151.7%]
(12)
6 0-23 + 0-01 0-31 + 0-01***
(6) [135-4%]
(8)
8 0-21+ 0-01 0-24+0-01***
(12) [118-0%J
(14)
12 0-22 + 0*01 0-25 + 0-01*
(12) [111-2%]
(10)
,B-Galactosidase
Propylene glycol MISO
2 ml/kg/day 400 mg/kg/day
1-12+0.02 1.23 + 0.02***
(12) [109.5%]
(18)
0.95+0.03 1-04+0-03
(10) [109-4%]
(18)
0-93 + 0.05 0*98+ 0*03
(14) [1052%]
(18)
1-02 + 0*04 1.25 + 0-06**
(10) [122-0%]
(10)
1-08 + 0-06 1-35 + 0.08*
(12) [124.8%]
(12)
1-03+0 04 1.19+0.03**
(6) [1154%]
(8)
1-05+ 0-02 1.15+0-02*
(12) [109.7%]
(14)
1-25+0-06 1*23+0 09
(12) [101.1%]
(10)
Significance difference from control: *P<0 05, **P<0-01, ***P<0-001.
Cumulative ,-
dose over
7 days r
MISO
administered
per day
(mg/kg)
50
100
200
300
500
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FIG. 2.-Effect of subacute administration of MISO on the fl-glucuronidase activity in 4 sections of
the sciatic/posterior tibial nerves from male and female Wistar rats.
Sampling time in weeks 1 2 3 4 5 6 8 12
Number of determinations
at each sampling time
MISO 18 18 18 20 12 8 14 10
Control 12 10 14 16 12 6 12 12
I I 7 consecutive daily doses; A A MISO 7 x 400 mg/kg/day; * * Propylene glycol
7 x 2 ml/kg/day.
Significant difference from mean control value: *P< 0-05, **P< 0-01, ***P< 0-001.
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FIG. 3.-Effect ofsubacute administration ofMISO on the B-galactosidase activity in 4 sections of the
sciatic/posterior tibial nerves from male and female Wistar rats. Symbols as in Fig. 2.
4 weeks after the start of dosing. By 12
weeks the enzyme activities had returned
to within the control range. The largest
and most significant increases were seen
in the most distal section (A). Progres-
sively smaller increases were found in
sections (B), (C) and (D); the enzyme
changes in (D) were not statistically sig-
nificant. On the basis of these findings
(Expt. I) enzyme activities in the 2 most
distal sections ofthe nerve (A and B) were
then analysed 4weeksaftertheadministra-
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TABLE III.-Effect of increasing doses of
MISO on the f3-glucuronidase and ,B-
galactosidase activities in the trigeminal
ganglia of male Wistar rats
Enzyme activity expressed as
,ug ofmethylumbelliferone
MISO liberated/h/mg
adminis-Cumulative (wet weight)
tered dose over r--
per day 7 days ,-Glucuron- P-Galactos-
(mg/kg) (mg/kg) idase idase
0 0-32+0-01 1-29+0*05
(20)
50 350 0-34+0-01
[106-3%]
(20)
100 700 0.35+0-01*
[111-4%]
(22)
200 1400 0-38+0-01**
[119.6%]
(14)
300 2100 0-42+0-01***
[133-2%]
(14)
500 3500 0.47 + 0-03***
[148-1%]
(6)
(20)
1-36+ 0.05
[105.1%]
(20)
1-46+ 0.05*
[112-9%]
(22)
1-45+ 0-06
[112-6%]
(14)
1-61 + 0.03**
[124-4%]
(14)
1-72+0.05***
[133-3%]
(6)
Significant difference from control: *P<0-05,
**P< 0.01, ***P< 0.001.
Enzyme activity measured 4 weeks after the start
of dosing.
tion of MISO at doses ranging from 50 to
500 mg/kg/day (Expt II). The results in
Table I indicate that the MISO-induced
increases in f-glucuronidase and P-galac-
tosidase activities were dose-related.
Significant increases in the activities of
P-glucuronidase and /-galactosidase were
also found in the trigeminal ganglia of
MISO-dosed animals. These activity in-
creases were maximal at 4-5 weeks (Table
II) and dose-related (Table III). A dose of
200/mg/kg/day MISO was required to
produce a statistically significant increase.
The /3-glucuronidase activity in the
cerebellum increased significantly after
MISO dosage. The increase was maximal
at 4 weeks (Table IV) and dose-related
(Table V). In contrast, the /-galactosidase
activity in the cerebellum decreased after
MISO, reaching a minimum at 5 weeks
(Table V). This decrease was also dose-
related (Table V).
TABLE V.-Effect of increasing doses of
MISO on the f-glucuronidase and fi-
galactosidase activities in the cerebellum
of male Wistar rats
MISO
per day
(mg/kg)
Cumulative
dose over
r 7 days
) (mg/kg)
Enzyme activity expressed as
,ug ofmethylumbelliferone
liberated/h/mg
II (wet weight)
,-Glucuron- ,-Galactos-
idase idase
0 0-89+ 0-02
(10)
50 350 0-87 x 0-02
[97.9%]
(10
100 700 0-89+ 0-02
[100.6%]
(11)
200 1400 0-96+0-03
[108.2%]
(7)
300 2100 1-02 + 003**
[114-8%]
(7)
500 3500 1.11+0.07***
[125.1%]
(3)
2-16+ 0-06
(10)
1-96 x 0.05*
[90.7%]
(10)
1-80+0.03**
[87.0%]
(11)
1-8+ 20-04**
[84.4%]
(7)
1-71 + 0-05***
[79.1%]
(7)
1-49 +0.07***
[69.3%]
(3)
Significant difference from control: *P< 0-05,
**P < 0.01, ***P < 0.001.
Enzyme activity measured 4 weeks after the start
ofdosing.
DISCUSSION
Subacute administration of high doses
of MISO elicited biochemical changes in
the sciatic/posterior tibial nerve (SPTN)
that were qualitatively similar to those
observed in Wallerian degeneration (Hol-
linger & Rossiter, 1952; McCaman &
Robins, 1959) and chemically induced
peripheral neuropathies (Dewar & Moffett,
1979; Dewar et al., 1979). In chemically
induced neuropathies of the dying-back
type (e.g. that produced by acrylamide)
the largest increases in P-glucuronidase
activity are found in the distal portion of
the nerve, with minimal changes in the
proximal portion (Dewar & Moffett, 1979).
In contrast, intheneuropathyproducedby
methyl mercury, the enzyme activity
increases appear contemporaneously along
the whole length of the nerve (Dewar &
Moffett, 1979). Thus, it may be concluded
that the enzyme activity increases found
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TABLE iv.-Effect of the subacute administration of MISO on the f3-glucuronidase and
/3-galactosidase activities in the cerebellum of male andfemale Wistar rats
Enzyme activity expressed as 4tg of methylumbelliferone liberated/h/mg
(wet weight)
P-Glucuronidase
Time of,
an
(w
,B-Galac
Lalysis Propylene glycol MISO Propylene glycol
'eeks) 2 ml/kg/day 400 mg/kg/day 2 ml/kg/day
1 0 39 + 0-02 0-47 + 0-01** 1-78 + 0-04
(6) [118-9%] (6)
(9)
2 0*33 + 0-01 0.45 + 0.02*** 2-05 + 0-18
(5) [137-2%] (5)
(9)
3 0 33+0-01 0.49+0-01*** 2-18+0*05
(14) [147-6%] (14)
(18)
4 0 40 + 0 03 0-83 + 0.04*** 2-01 + 0-06
(8) [205.5%] (8)
(10)
5 0-31 +0-02 0-44+0.03** 1-95+0-10
(6) [142-1%] (6)
(6)
6 0-32 + 0-01 0-42 + 0-01** 1-80+ 0-08
(3) [i32-9%] (3)
(4)
8 0*54+0-02 0 54+0-02 2-32+0-10
(6) [106-0%] (6)
(7)
12 0*59+0-02 0 57+0-01 2-61 +0-1
(6) [97 3%] (6)
(5)
Significant difference from control: **P< 0-01, ***P< 0-001.
in the SPTN of MISO-dosed rats are con-
sistent with a dying-back neuropathy.
On the basis of the data in Table I a
cumulative dose of2-1 g or more isrequired
to produce biochemical changes consistent
with peripheral neuropathy. However,
even at doses of MISO sufficient to kill a
proportion of the animals, the mean
increases in 3-glucuronidase and ,B-galacto-
sidase in the most affected part of the
nerve were relatively small ( <80%;
Table I, Figs 2 and 3). This is considerably
less than the increases of 300-600% that
have been found after neurotoxic doses of
acrylamide or methyl mercury (Kaplan &
Murphy, 1972; Dewar & Moffett, 1979).
This suggests that the peripheral nerve
damage produced by MISO, even at near
lethal doses, is small compared with that
produced by neurotoxic doses of acryla-
mide and methyl mercury.
-tosidase
MISO
400 mg/kg/day
1-34 + 0.05***
[75-1%]
(9)
1-66 + 0.09**
[80.7%]
(9)
1-55 + 0.05***
[70.9%]
(18)
1-45 + 0.06***
[71.9%]
(10)
1-36 + 0-08**
[69.8%]
(6)
1-18+0.03**
[65-8%]
(4)
2.21 + 0*09
[95.1%]
(7)
2-62+0-14
[100.7%]
(5)
Methyl mercury, a compoundwhich pro-
duces sensory neuropathy in rats, has been
shown to increase ,B-glucuronidase and /3-
galactosidase activities in the trigeminal
ganglia (Dewar & Moffett, 1979). Qualita-
tively similar (i.e. in time course) but
smaller changes were found in the tri-
geminal ganglia of MISO-treated rats.
This suggests degeneration in the tri-
geminal ganglia, or possibly a chromato-
lyticresponse intheneuronesoftheganglia
to degeneration in the axons of the tri-
geminal nerve. In either case the bio-
chemical evidence suggests that MISO
affects sensory nerve fibres. This is con-
sistent with MISO-induced neuropathy in
humans, which is believed to be primarily
sensory (Dische et al., 1977; Urtasun et al.,
1977).
There is evidence that certain types of
degeneration in the CNS are accompanied
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by large increases in 3-glucuronidase
activity. This is particularly true of de-
generation in which cellular proliferation
is a feature, e.g. the encephalopathy pro-
duced by the copper-chelating agent
cuprizone (Bowen et al., 1974). There is
also evidence that 3-galactosidase can be
regarded as a neuronal marker in the CNS
(Sinha & Rose, 1972) and that neuronal
damage or loss is accompanied by a reduc-
tion in the activity of this enzyme, e.g.
in the encephalopathy produced by Sem-
liki Forest virus (Bowen et al., 1974). On
the basis ofthis evidence the results shown
in Tables IV and V suggest that MISO can
induce degenerative changes in the rat
cerebellum.
Shortly after this biochemical study
was completed, a detailed neuropatho-
logical examination of the effects of MISO
on rats was published (Griffin et al., 1979).
The results of that study were consistent
with the biochemical findings reported
here, in that there was evidence of a mild
dying-back peripheral neuropathy. Fur-
thermore, necrosis and degeneration ofthe
cerebellar-roofnuclei was reported. Neuro-
pathological evidence of damage to cere-
bellar Purkinje cells has been found in
dogs dosed with nitroimidazole derivatives
(Scharer, 1972).
In summary, we have obtained bio-
chemical evidence to suggest that misoni-
dazole, when administered in large doses
to rats, produces a mild dying-back neuro-
pathy, which is consistent with available
neuropathological evidence. Since this
biochemical method of detecting chemi-
cally induced neuropathy is technically
simple and can be performed rapidly on a
large number of nerve samples, it would
appear to offer a simple sensitive method
for screening other candidate radiosensi-
tizing drugs for neurotoxic effects. The
biochemical technique has the advantage
that it yields data in a quantitative form
which can be used for the construction of
dose-response graphs, thus enabling con-
venient comparison between the neuro-
toxic effects of different drugs. In our
experience (Rose & Dewar, 1980) alterna-
tive methods, such as behavioural or func-
tional tests are ineffective in detecting the
neurotoxic effects of MISO reliably. A
similar biochemical approach couldbe used
for screening for possible neurotoxic effects
in the cerebellum, but here the correlation
between the biochemical findings and the
neuropathy is less defined and may require
further investigation.
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